106 related articles for article (PubMed ID: 6578393)
1. Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia.
Baccarani M; Zaccaria A; Bandini G; Cavazzini G; Fanin R; Tura S
Leuk Res; 1983; 7(4):539-45. PubMed ID: 6578393
[TBL] [Abstract][Full Text] [Related]
2. Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia.
Alessandrino EP; Orlandi E; Brusamolino E; Lazzarino M; Bernasconi C
Am J Hematol; 1985 Oct; 20(2):191-3. PubMed ID: 4036958
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
4. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine.
Ho AD; Schwarz CE; Hunstein W
Leuk Res; 1985; 9(10):1293-8. PubMed ID: 3865029
[TBL] [Abstract][Full Text] [Related]
6. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
7. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
[TBL] [Abstract][Full Text] [Related]
8. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia.
Hellström-Lindberg E; Robèrt KH; Gahrton G; Lindberg G; Forsblom AM; Kock Y; Ost A
Br J Haematol; 1992 Aug; 81(4):503-11. PubMed ID: 1390236
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
10. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study.
Preisler HD; Raza A; Barcos M; Azarnia N; Larson R; Browman G; Walker I; Grunwald H; D'Arrigo P; Stein A
Am J Hematol; 1986 Oct; 23(2):131-4. PubMed ID: 3529939
[TBL] [Abstract][Full Text] [Related]
12. [Small-dose cytarabine (Ara-C) in the treatment of myelodysplastic syndrome].
Dan K; Ogata K; Gomi S; Ohki I; Kuwabara T; Horikoshi H; Nomura T
Rinsho Ketsueki; 1984 Oct; 25(10):1600-5. PubMed ID: 6596446
[No Abstract] [Full Text] [Related]
13. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
De Witte T; Muus P; De Pauw B; Haanen C
Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia.
Roberts JD; Ershler WB; Tindle BH; Stewart JA
Cancer; 1985 Sep; 56(5):1001-5. PubMed ID: 3860278
[TBL] [Abstract][Full Text] [Related]
15. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
16. Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro.
Katagiri T; Miyazawa K; Nishimaki J; Yaguchi M; Kawanishi Y; Ohyashiki K
Leuk Lymphoma; 2000 Sep; 39(1-2):173-84. PubMed ID: 10975397
[TBL] [Abstract][Full Text] [Related]
17. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
Aul C; Schneider W
Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
[TBL] [Abstract][Full Text] [Related]
18. In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
Motta MR; Baccarani M; Rizzi S; Fanin R; Fasola G; Poluzzi C; Tura S
Blut; 1987 May; 54(5):299-306. PubMed ID: 3567369
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
20. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
Jehn U; Göldel N; Vehling-Kaiser U
Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
